期刊
CHEMISTRY-A EUROPEAN JOURNAL
卷 21, 期 43, 页码 15308-15319出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/chem.201502154
关键词
anthraquinones; cyclometalation; cytotoxicity; hypoxia; ruthenium
资金
- 973 program [2015CB856301]
- National Science Foundation of China [21172273, 21171177, 21471164, J1103305]
- Program for Changjiang Scholars and Innovative Research Team in University of China [IRT1298]
Hypoxia is the critical feature of the tumor microenvironment that is known to lead to resistance to many chemotherapeutic drugs. Six novel ruthenium(II) anthraquinone complexes were designed and synthesized; they exhibit similar or superior cytotoxicity compared to cisplatin in hypoxic HeLa, A549, and multidrug-resistant (A549R) tumor cell lines. Their anticancer activities are related to their lipophilicity and cellular uptake; therefore, these physicochemical properties of the complexes can be changed by modifying the ligands to obtain better anticancer candidates. Complex 1, the most potent member of the series, is highly active against hypoxic HeLa cancer cells (IC50=0.53M). This complex likely has 46-fold better activity than cisplatin (IC50=24.62M) in HeLa cells. This complex tends to accumulate in the mitochondria and the nucleus of hypoxic HeLa cells. Further mechanistic studies show that complex 1 induced cell apoptosis during hypoxia through multiple pathways, including those of DNA damage, mitochondrial dysfunction, and the inhibition of DNA replication and HIF-1 expression, making it an outstanding candidate for further in vivo studies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据